MRK · News · 20260930N
Acquisition / Partnership / Divestiture
Merck & Co., Inc. · 2026-09-30 · Importance 71 · Surprise 60 · Contradicted
Merck completed its acquisition of Prometheus Biosciences in June 2023 for $10.8 billion. The transaction valued Prometheus at $200 per share, representing a 75% premium to its unaffected closing price. Prometheus specialized in inflammatory bowel disease therapies and became a wholly owned Merck subsidiary after the acquisition.
Key facts
- Merck & Co., Inc. acquired Prometheus Biosciences for $10.8 billion in June 2023. source
- Merck & Co., Inc. paid $200.00 per share to acquire Prometheus Biosciences. source
- Merck & Co., Inc. paid a 75% premium per share when acquiring Prometheus Biosciences. source
- Prometheus Biosciences is now a wholly-owned subsidiary of Merck & Co., Inc. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +8.3% | Merck & Co., Inc. acquired Prometheus Biosciences for $10.8 billion in June 2023. |